Showing 1–16 of 32 results
ARA-290 is a variant of erythropoietin that has been shown to reduce inflammation by targeting paracrine signaling and activating innate repair receptors. Research indicates that ARA-290 may help lower HbA1c levels, improve cholesterol profiles, modulate neuropathic pain, and promote wound healing.
Maximize your research with this high-potency combo: BPC-157 and TB-500, each at 10mg. Designed for advanced studies into tissue repair, recovery, and overall regeneration.
A powerful duo—BPC-157 and TB-500, each 5mg. Get the benefits of both peptides in one convenient combo. Ideal for research focused on recovery, regeneration, and performance.
BPC-157, or Body Protection Compound 157, is a synthetic peptide consisting of 15 amino acids. It is derived from a naturally occurring protective protein found in human gastric juice and has been extensively studied for its therapeutic potential. BPC-157 is renowned for its regenerative properties, with research indicating its ability to promote healing in various tissues, including muscles, tendons, ligaments, and the gastrointestinal tract, particularly in inflammatory conditions. Its broad biological effects have attracted significant interest in both scientific and medical communities as a promising candidate for treating injuries, chronic diseases, and inflammation-related disorders.
BPC-157, or Body Protection Compound 157, is a synthetic peptide consisting of 15 amino acids. It is derived from a naturally occurring protective protein found in human gastric juice and has been extensively studied for its therapeutic potential. BPC-157 is renowned for its regenerative properties, with research indicating its ability to promote healing in various tissues, including muscles, tendons, ligaments, and the gastrointestinal tract, particularly in inflammatory conditions. Its broad biological effects have attracted significant interest in both scientific and medical communities as a promising candidate for treating injuries, chronic diseases, and inflammation-related disorders.
Powerful peptide synergy: CJC-1295 and Ipamorelin, each 5mg per vial. Popular in research exploring growth hormone release, recovery enhancement, and anti-aging pathways. Two peptides—one streamlined combo.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to elevate plasma levels of growth hormone and insulin-like growth factor 1 (IGF-1). The inclusion of a Drug Affinity Complex (DAC) extends the plasma half-life of CJC-1295, enhancing its stability and duration of action.
FOXO4-DRI is a synthetic, modified version of the naturally occurring FOXO4 protein, engineered using a retro-inverso peptide structure to enhance stability and prolong its half-life in biological systems. This structural modification allows FOXO4-DRI to interfere with the normal interaction between FOXO4 and the tumor suppressor protein p53.
GHK-Cu is a naturally occurring peptide found in human blood plasma, urine, and saliva. Animal studies have shown that it supports wound healing, enhances immune function, and promotes skin regeneration by stimulating collagen production, activating fibroblasts, and encouraging blood vessel formation. Evidence also suggests that GHK-Cu acts as a feedback signal triggered by tissue injury. Additionally, it helps protect against oxidative stress by suppressing free radical damage, making it a powerful antioxidant.
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic growth hormone secretagogue that binds to the ghrelin/growth hormone secretagogue receptor (GHS-R). By activating this receptor, GHRP-2 stimulates the natural release of growth hormone from the pituitary gland.
Research studies have demonstrated that GHRP-2 can enhance muscle growth, support immune system regulation, and promote healthier sleep cycles. Notably, GHRP-2 also exhibits oral bioactivity, a rare trait among peptide therapeutics, making it a potential candidate for non-injectable applications in future research settings.
Tirzepatide was originally developed to treat type 2 diabetes, but it has also demonstrated protective effects on the cardiovascular system. It is a synthetic analog of gastric inhibitory polypeptide (GIP) that also mimics the actions of glucagon-like peptide-1 (GLP-1). This dual mechanism helps reduce blood glucose levels, enhance insulin sensitivity, and promote a sense of satiety.
Tirzepatide is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) activity. This dual mechanism enables it to reduce blood glucose levels, enhance insulin sensitivity, and promote satiety. Originally developed for the treatment of type 2 diabetes, Tirzepatide has also demonstrated cardiovascular protective effects.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose metabolism. As a GLP-1 receptor agonist, Semaglutide mimics the effects of endogenous GLP-1, promoting insulin secretion and suppressing glucagon release in a glucose-dependent manner—a mechanism that helps lower blood sugar without causing hypoglycemia.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose metabolism. As a GLP-1 receptor agonist, Semaglutide mimics the effects of endogenous GLP-1, promoting insulin secretion and suppressing glucagon release in a glucose-dependent manner—a mechanism that helps lower blood sugar without causing hypoglycemia.
Humanin is a naturally occurring micro-peptide located in the mitochondria, where it plays a critical role in cellular protection. It is best known for its ability to prevent apoptosis (programmed cell death), helping to preserve cell viability under stress. As one of the few compounds that directly influence mitochondrial function, Humanin supports improved energy efficiency and cellular homeostasis. Ongoing research suggests it may have therapeutic potential in preventing or mitigating diseases of the heart, eyes, brain, and skeletal muscles.
IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arginine 3) is a synthetic, modified analog of IGF-1. Due to its reduced affinity for IGF-binding proteins, IGF-1 LR3 remains active in circulation up to 120 times longer than native IGF-1. This significantly extended half-life leads to enhanced and prolonged biological activity. IGF-1 LR3 promotes cell division and growth, stimulates fat metabolism, and supports muscle repair and hypertrophy by inhibiting the muscle-growth limiting protein myostatin. Emerging research also suggests a potential role for IGF-1 LR3 in improving lactation in mothers with young offspring.
